• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

CHMP adopts positive opinion regarding Atectura Breezhaler and Bemrist Breezhaler

At a March 27, 2020 meeting of the EMA’s Committee for Medicinal Products for Human Use (CHMP), the committee adopted a positive opinion regarding the MAAs for Novartis’s Atectura Breezhaler indacaterol/mometasone furoate and a duplicate inhaler, Bemrist Breezhaler. Both will be available in 125 mcg/260 mcg, 125 mcg/127.5 mcg and 125 mcg/62.5 mcg strengths for the treatment of asthma in patients aged 12 and older once approved.

In May 2019, Novartis announced that the Phase 3 QUARTZ study had demonstrated that QMF149 indacaterol/mometasone furoate delivered via the Breezhaler DPI produced statistically significant and clinically meaningful lung function and asthma control improvements compared to mometasone furoate alone.

At that time, Novartis said that an MAA for QMF149 had been accepted by the EMA and was under review, as was a submission for its QVM149 indacaterol/glycopyrronium/mometasone DPI.

Read the CHMP summary of the positive opinion for Atectura Breezhaler.
Read the CHMP summary of the positive opinion for Bemrist Breezhaler.

Share

published on March 31, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews